NEUROSENSE THERAPEUTICS LTD
NRSN · NASDAQ
Updated at 2026-10-13 12:15:48
- Today's High
- --
- Today’s Low
- --
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $3.66
- Previous Close
- $3.48
- Volume
- 7.42K
- Market Cap
- $6.6M
- P/E Ratio
- --
- EPS
- $-10.78
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Biotechnology
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- BUILDING B, HERZLIYA, ISRAEL, 4672562
- Country
- IL
- Listing Date
- 2021-12-09
- Fiscal Year End
- December
- Shares Outstanding
- 35.35M
- CIK
- 0001875091
- Website
- www.neurosense-tx.com
Neurosense Therapeutics Ltd (NRSN) is a clinical-stage biotechnology firm dedicated to innovating treatments for neurodegenerative diseases, with a particular emphasis on Parkinson's disease. The company is advancing a diverse pipeline of therapeutic candidates through pivotal clinical trials, addressing critical unmet needs in neurology. With a seasoned management team and strategic partnerships, Neurosense is poised to develop groundbreaking therapies that not only enhance patient outcomes but also bolster its competitive position in the biopharmaceutical sector.
Financial Metrics
Revenue
2025-12-31
--
2025-09-30
--
2025-06-30
--
2025-03-31
--
Operating Expenses
2025-12-31
$3.19M
2025-09-30
$3.19M
2025-06-30
$2.34M
2025-03-31
$2.34M
Net Income
2025-12-31
-$3.2M
2025-09-30
-$3.2M
2025-06-30
-$2.35M
2025-03-31
-$2.35M
Net Profit Margin
2025-12-31
--
2025-09-30
--
2025-06-30
--
2025-03-31
--
Earnings Per Share
2025-12-31
$0.00
2025-09-30
$-0.04
2025-06-30
$-0.19
2025-03-31
$-0.06
Earnings Before Interest, Taxes, Depreciation, and Amortization
2025-12-31
-$3.19M
2025-09-30
-$3.19M
2025-06-30
-$2.34M
2025-03-31
-$2.34M
Effective Tax Rate
2025-12-31
--
2025-09-30
--
2025-06-30
--
2025-03-31
--
| Item | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Revenue | -- | -- | -- | -- |
| Operating Expenses | $3.19M | $3.19M | $2.34M | $2.34M |
| Net Income | -$3.2M | -$3.2M | -$2.35M | -$2.35M |
| Net Profit Margin | -- | -- | -- | -- |
| Earnings Per Share | $0.00 | $-0.04 | $-0.19 | $-0.06 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$3.19M | -$3.19M | -$2.34M | -$2.34M |
| Effective Tax Rate | -- | -- | -- | -- |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.